Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic …
JB Briere, K Bowrin, C Coleman… - Expert Review of …, 2019 - Taylor & Francis
Introduction: Several comparative real-world effectiveness studies on direct oral
anticoagulants (DOACs) have been conducted, but an overview of the available evidence …
anticoagulants (DOACs) have been conducted, but an overview of the available evidence …
Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular …
CI Coleman, JB Briere, L Fauchier, P Levy… - Journal of market …, 2019 - mdpi.com
Introduction: Numerous real-world studies have compared non-vitamin K antagonist oral
anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular …
anticoagulants (NOACs) with vitamin K antagonists (VKAs) in patients with non-valvular …
Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis
S Deitelzweig, E Bergrath, M di Fusco, A Kang… - Future …, 2022 - Future Medicine
Aim: To compare real-world effectiveness/safety of non-vitamin K antagonist oral
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …
anticoagulants and vitamin K antagonists among patients with non-valvular atrial fibrillation …
Safety and efficacy of direct acting oral anticoagulants and vitamin K antagonists in nonvalvular atrial fibrillation–a network meta-analysis of real-world data
M Hirschl, M Kundi - Vasa, 2018 - econtent.hogrefe.com
Background: In randomized controlled trials (RCTs) direct acting oral anticoagulants
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …
(DOACs) showed a superior risk-benefit profile in comparison to vitamin K antagonists …
Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach
P Verdecchia, F Angeli, C Bartolini… - Expert Opinion on …, 2015 - Taylor & Francis
Introduction: Choosing between different non-vitamin K antagonist oral anticoagulants
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …
(NOACs) in non-valvular atrial fibrillation (NVAF) is difficult due to the absence of head to …
A comparison of front-line oral anticoagulants for the treatment of non-valvular atrial fibrillation: effectiveness and safety of direct oral anticoagulants in the FANTASIIA …
MA Esteve-Pastor, JM Rivera-Caravaca… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction For a long time, vitamin K antagonists (VKA) were the only oral anticoagulation
therapy available to reduce adverse events in atrial fibrillation (AF) patients. Direct-acting …
therapy available to reduce adverse events in atrial fibrillation (AF) patients. Direct-acting …
Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the …
JB Briere, O Wu, K Bowrin, A Millier… - Current Medical …, 2019 - Taylor & Francis
Objective: The aim of this study was to investigate the impact of methodological choices in a
meta-analysis of real-world evidence (RWE) comparing three non-vitamin-K antagonist oral …
meta-analysis of real-world evidence (RWE) comparing three non-vitamin-K antagonist oral …
[HTML][HTML] Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation
JC Lega, L Bertoletti, C Gremillet, C Chapelle… - PloS one, 2014 - journals.plos.org
Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran …
Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …
[HTML][HTML] Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort …
M Grymonprez, TL De Backer, X Bertels… - Frontiers in …, 2023 - frontiersin.org
Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …
recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management …